Skip to main content
The state and consequences of dermatology drug prices in the United States
University of Massachusetts Medical School Faculty Publications
  • Joerg Albrecht, Rush Medical College
  • Mary E. Maloney, University of Massachusetts Medical School
  • Bruce Alan Brod, University of Pennsylvania
UMMS Affiliation
Division of Dermatology, Department of Medicine
Document Type

In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.

Rights and Permissions
Citation: J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site

Full author list omitted for brevity. For full list of authors see article.

Related Resources
Link to Article in PubMed
  • coinsurances,
  • drug pricing,
  • formulary tiering,
  • generic drugs,
  • out-of-pocket costs,
  • pharmacy benefit managers,
  • prior authorizations
PubMed ID
Citation Information
Joerg Albrecht, Mary E. Maloney and Bruce Alan Brod. "The state and consequences of dermatology drug prices in the United States" Vol. 75 Iss. 3 (2016) ISSN: 0190-9622 (Linking)
Available at: